اشترك بالحزمة الذهبية واحصل على وصول غير محدود شمرا أكاديميا
تسجيل مستخدم جديدAutoencoders as Weight Initialization of Deep Classification Networks for Cancer versus Cancer Studies
113
0
0.0
(
0
)
اسأل ChatGPT حول البحث
ﻻ يوجد ملخص باللغة العربية
Cancer is still one of the most devastating diseases of our time. One way of automatically classifying tumor samples is by analyzing its derived molecular information (i.e., its genes expression signatures). In this work, we aim to distinguish three different types of cancer: thyroid, skin, and stomach. For that, we compare the performance of a Denoising Autoencoder (DAE) used as weight initialization of a deep neural network. Although we address a different domain problem in this work, we have adopted the same methodology of Ferreira et al.. In our experiments, we assess two different approaches when training the classification model: (a) fixing the weights, after pre-training the DAE, and (b) allowing fine-tuning of the entire classification network. Additionally, we apply two different strategies for embedding the DAE into the classification network: (1) by only importing the encoding layers, and (2) by inserting the complete autoencoder. Our best result was the combination of unsupervised feature learning through a DAE, followed by its full import into the classification network, and subsequent fine-tuning through supervised training, achieving an F1 score of 98.04% +/- 1.09 when identifying cancerous thyroid samples.
قيم البحث
اقرأ أيضاً
Cancer is a complex disease, the understanding and treatment of which are being aided through increases in the volume of collected data and in the scale of deployed computing power. Consequently, there is a growing need for the development of data-dr
iven and, in particular, deep learning methods for various tasks such as cancer diagnosis, detection, prognosis, and prediction. Despite recent successes, however, designing high-performing deep learning models for nonimage and nontext cancer data is a time-consuming, trial-and-error, manual task that requires both cancer domain and deep learning expertise. To that end, we develop a reinforcement-learning-based neural architecture search to automate deep-learning-based predictive model development for a class of representative cancer data. We develop custom building blocks that allow domain experts to incorporate the cancer-data-specific characteristics. We show that our approach discovers deep neural network architectures that have significantly fewer trainable parameters, shorter training time, and accuracy similar to or higher than those of manually designed architectures. We study and demonstrate the scalability of our approach on up to 1,024 Intel Knights Landing nodes of the Theta supercomputer at the Argonne Leadership Computing Facility.
The emerging field of precision oncology relies on the accurate pinpointing of alterations in the molecular profile of a tumor to provide personalized targeted treatments. Current methodologies in the field commonly include the application of next ge
neration sequencing technologies to a tumor sample, followed by the identification of mutations in the DNA known as somatic variants. The differentiation of these variants from sequencing error poses a classic classification problem, which has traditionally been approached with Bayesian statistics, and more recently with supervised machine learning methods such as neural networks. Although these methods provide greater accuracy, classic neural networks lack the ability to indicate the confidence of a variant call. In this paper, we explore the performance of deep Bayesian neural networks on next generation sequencing data, and their ability to give probability estimates for somatic variant calls. In addition to demonstrating similar performance in comparison to standard neural networks, we show that the resultant output probabilities make these better suited to the disparate and highly-variable sequencing data-sets these models are likely to encounter in the real world. We aim to deliver algorithms to oncologists for which model certainty better reflects accuracy, for improved clinical application. By moving away from point estimates to reliable confidence intervals, we expect the resultant clinical and treatment decisions to be more robust and more informed by the underlying reality of the tumor molecular profile.
Machine learning (ML) offers a collection of powerful approaches for detecting and modeling associations, often applied to data having a large number of features and/or complex associations. Currently, there are many tools to facilitate implementing
custom ML analyses (e.g. scikit-learn). Interest is also increasing in automated ML packages, which can make it easier for non-experts to apply ML and have the potential to improve model performance. ML permeates most subfields of biomedical research with varying levels of rigor and correct usage. Tremendous opportunities offered by ML are frequently offset by the challenge of assembling comprehensive analysis pipelines, and the ease of ML misuse. In this work we have laid out and assembled a complete, rigorous ML analysis pipeline focused on binary classification (i.e. case/control prediction), and applied this pipeline to both simulated and real world data. At a high level, this automated but customizable pipeline includes a) exploratory analysis, b) data cleaning and transformation, c) feature selection, d) model training with 9 established ML algorithms, each with hyperparameter optimization, and e) thorough evaluation, including appropriate metrics, statistical analyses, and novel visualizations. This pipeline organizes the many subtle complexities of ML pipeline assembly to illustrate best practices to avoid bias and ensure reproducibility. Additionally, this pipeline is the first to compare established ML algorithms to ExSTraCS, a rule-based ML algorithm with the unique capability of interpretably modeling heterogeneous patterns of association. While designed to be widely applicable we apply this pipeline to an epidemiological investigation of established and newly identified risk factors for pancreatic cancer to evaluate how different sources of bias might be handled by ML algorithms.
We present a deep convolutional neural network for breast cancer screening exam classification, trained and evaluated on over 200,000 exams (over 1,000,000 images). Our network achieves an AUC of 0.895 in predicting whether there is a cancer in the b
reast, when tested on the screening population. We attribute the high accuracy of our model to a two-stage training procedure, which allows us to use a very high-capacity patch-level network to learn from pixel-level labels alongside a network learning from macroscopic breast-level labels. To validate our model, we conducted a reader study with 14 readers, each reading 720 screening mammogram exams, and find our model to be as accurate as experienced radiologists when presented with the same data. Finally, we show that a hybrid model, averaging probability of malignancy predicted by a radiologist with a prediction of our neural network, is more accurate than either of the two separately. To better understand our results, we conduct a thorough analysis of our networks performance on different subpopulations of the screening population, model design, training procedure, errors, and properties of its internal representations.
This report assesses different machine learning approaches to 10-year survival prediction of breast cancer patients.
الأسئلة المقترحة
سجل دخول لتتمكن من نشر تعليقات
التعليقات
جاري جلب التعليقات
سجل دخول لتتمكن من متابعة معايير البحث التي قمت باختيارها
